Trial
NCT04150757
Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Abigail Nixon
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Intranasal ketamine
Why stopped
Poor recruitment secondary to COVID
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-18